Center for Biosimilars®
WEBSeptember 24th 2024. Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
Rituximab Biosimilars Effective in Treating Immune …
WEBJan 15, 2024 · A French study found that rituximab biosimilars, Rixathon and Truxima, were as effective and safe as the reference drug (Rituxan) in treating immune thrombocytopenia. Two rituximab biosimilars (Rixathon and Truxima) and the reference drug (Rituxan) exhibited similar safety and efficacy outcomes in patients with …
Conferences - Center for Biosimilars
WEBASCO. ASCO GI. American Academy of Dermatology. American College of Gastroenterology Annual Scientific Meeting. American College of Rheumatology Annual Meeting. American Conference Institute: Summit on Biosimilars & Innovator Biologics. American Society of Hematology Annual Meeting and Exposition. Annual J.P. Morgan Healthcare Conference. Asembia.
New Data Show Safety of Ado-Trastuzumab, Trastuzumab …
WEBJun 11, 2024 · Another study evaluated the safety and efficacy of a biosimilar of ado-trastuzumab emtansine (Kadcyla; TDM1) in patients with HER2+ breast cancer. 2 Although the antibody drug conjugate has shown efficacy in treating HER+ breast cancer, the high cost of the reference product limits its use in low- …
Ophthalmology - Center for Biosimilars
WEBOct 19, 2019 · Skylar Jeremias. May 20th 2024. The FDA approved the first 2 biosimilars referencing Eylea (aflibercept)—Yesafili (aflibercept-jbvf) and Opuviz (aflibercept-yszy)—for the treatment of ophthalmic conditions. Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth.
Promoting Informed Decision-Making Through Biosimilar Awareness
WEBSep 8, 2024 · Promoting Informed Decision-Making Through Biosimilar Awareness. Ivo Abraham, PhD, RN, University of Arizona Cancer Center, urges stakeholders to provide patient advocacy groups with comprehensive information about specific drugs and drug classes to increase patient understanding of biosimilars …
No Differences in Long-Term Drug Survival Between Biosimilar ...
WEBAug 15, 2024 · No significant differences in long-term survival due to inefficacy or adverse events were found between subcutaneous biosimilar and originator tumor necrosis factor (TNF) inhibitors for rheumatic diseases, as shown by a retrospective analysis published in The Journal of Rheumatology. 1. “In real-world practice, this can be reassuring when ...
FDA Approves First Subcutaneous Infliximab Product - Center for …
WEBOct 23, 2023 · The FDA approved Celltrion USA’s Zymfentra (infliximab-dyyb), the world’s first and only subcutaneous infliximab product. Zymfentra is approved as a novel drug, and its development is based on Remicade (reference intravenous infliximab). The intravenous version of Zymfentra is marketed as Inflectra (also, infliximab-dyyb), Celltrion's ...
Diabetes - centerforbiosimilars.com
WEBIRA Insulin Cap Could Have Saved Medicare Beneficiaries Millions in 2020. A new report from HHS has revealed that if the Inflation Reduction Act (IRA) had been implemented in 2020, Medicare Part D beneficiaries could have saved a total of $734 million, averaging out to about $500 per member.
Biosimilars and Employers: Strategies for Success
WEBJul 8, 2024 · Prior authorization is one of the most common utilization management (UM) strategies used by employers and payers. In theory, this UM technique helps ensure appropriate use of selected drugs. Biosimilars should be included in this PA process as a high quality, less costly alternative to more expensive biologic drugs.